

Date: 29.03.2024

To,

Department of Corporate Services Bombay Stock Exchange Limited Floor 25, PJ Towers Dalal Street, Mumbai – 400 001	National Stock Exchange of India Ltd Exchange Plaza Bandra Kurla Complex Bandra (E), Mumbai 400 051
---	---

Dear Sir,

Sub: Outcome of the Board Meeting held on 29.03.2024

Pursuant to Regulation 30 and 33 of SEBI (Listing obligations and disclosure requirements) 2015, this is to inform you that the Board of Directors in their just concluded Board meeting held today have:

1. Considered and adopted the standalone and consolidated audited financial results of the Company for the quarter / year ended 31.03.2023;
2. Considered and adopted the standalone and consolidated un-audited financial results of the Company for the quarter / three months ended 30.06.2023;
3. Considered and adopted the standalone and consolidated un-audited financial results of the Company for the quarter / half year ended 30.09.2023;
4. Considered and adopted the standalone and consolidated un-audited financial results of the Company for the quarter / nine months ended 31.12.2023;

In this connection find attached the following:

1. Copy of standalone and consolidated audited financial results of the Company for the quarter / year ended 31.03.2023 alongwith Audit Report & declaration of unmodified opinion.
2. Copy of standalone and consolidated un-audited financial results of the Company for the quarter / three months ended 30.06.2023 alongwith Limited Review Report
3. Copy of standalone and consolidated un-audited financial results of the Company for the quarter / half year ended 30.09.2023 alongwith Limited Review Report
4. Copy of standalone and consolidated un-audited financial results of the Company for the quarter / nine months ended 31.12.2023 alongwith Limited Review Report

The meeting commenced at 3.30 PM and ended at 6.45 PM.

This is for your information and records.

Thanking you
Yours truly

For Celestial Biolabs Limited

**AMIT
KUMAR
SINGH**

Digitally signed by
AMIT KUMAR SINGH
Date: 2024.03.29
18:46:14 +05'30'

Amit Kumar Singh
Managing Director
DIN: 01824426



LIMITED REVIEW REPORT

To,
The Board Members of
Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited standalone financial results of M/s Celestial Biolabs Limited for quarter ended 31 December ,2023", and year to date results for the period from 01 April 2023 to 31 December 2023 ("The statement")

The statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone Financial Results , prepared in accordance with applicable accounting standards specified under section 33 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.



We draw your attention to note 4 to the Standalone financial results, where the management had commented that the previous year comparatives are based on the financial statements approved by the board of directors but not yet adopted by the shareholders in the annual General Meeting (AGM) as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting. Our review is carried on based on these unadopted financial results carried forward to the current period.

We draw attention to Note 5 to the Standalone financial results, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 5 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

Our conclusion is not modified in respect of this matter

For **M Surendra & Associates**
Chartered Accountants
Firm Reg No. 0172805



CA Shaik Shavali P
Partner
M.No. 245517



Place : Hyderabad
Date: 29.03.2024

UDIN: 24245517BKDASH3270

CELESTIAL BIOLABS LIMITED
Plot No.59, Road No.12, TSIC Tech Park, IDA Nacharam, Hyderabad-500 076
STANDALONE STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st Dec, 2023

SL.NO.	PARTICULARS	Rs In lacs					
		Quarter Ended			Nine month period ended		Year Ended
		31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.03.2023 (Audited)
I	a) Revenue from operations	3.68	3.58	3.38	9.53	13.07	16.87
II	b) Other Income	-	-	-	-	-	-
III	Total income (I+II)	3.68	3.58	3.38	9.53	13.07	16.87
IV	Expenditure						
	a) Cost of raw and packing materials consumed	2.36	2.17	2.15	5.86	8.02	10.61
	b) Purchase of Traded Products	-	-	-	-	-	-
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	-	-	-	-	-	-
	d) Employee Benefits Expense	2.67	3.01	5.15	9.78	13.86	20.04
	e) Depreciation and amortization	0.54	0.54	0.70	1.62	2.10	2.83
	f) Finance Cost	0.07	0.04	0.07	0.15	0.22	0.23
	g) Other Expenses	1.48	1.08	10.58	8.68	22.47	40.34
	Total expenses	7.11	6.84	18.65	26.08	46.67	74.05
V	Profit / (Loss) before exceptional items and Tax (III-IV)	(3.43)	(3.26)	(15.27)	(16.56)	(33.60)	(57.18)
VI	Exceptional items	-	-	-	-	-	-
VII	Profit / (Loss) before tax (V-VI)	(3.43)	(3.26)	(15.27)	(16.56)	(33.60)	(57.18)
VIII	Tax expense	-	-	-	-	-	-
IX	Net Profit / (Loss) for the period (VII-VIII)	(3.43)	(3.26)	(15.27)	(16.56)	(33.60)	(57.18)
X	Other Comprehensive Income,	-	-	-	-	-	-
	Total Other Comprehensive Income, net of Tax	-	-	-	-	-	-
XI	Total Comprehensive Income for the period	(3.43)	(3.26)	(15.27)	(16.56)	(33.60)	(57.18)
XII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63
XIII	Earning Per Share for the Period						
	Basic	(0.02)	(0.01)	(0.07)	(0.07)	(0.15)	(0.25)
	Diluted	(0.02)	(0.01)	(0.07)	(0.07)	(0.15)	(0.25)

- Notes
- The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 29.03.2024
 - Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
 - The Financial results and other financial information for the quarter ended 31st December, 2023 has been compiled by the management as per Ind AS, after exercising necessary due diligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only subject to review of statutory auditors. Results are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com
 - The previous year comparatives are based on the audited financial statements which are approved by the board of directors but yet to be adopted by the shareholders in the upcoming Annual general meeting as the company has not complied with section 96 of the companies act 2013 regarding conduct of Annual general meeting
 - During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs. Consequently, the Networth which was at 10,227.30 at the beginning of the financial year 2019-20 came down to Rs. 277.86 lakhs for year ended 31.3.2023. Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation
 - The company acquired 51.01% shares in X Ploro Chemistry capability centre Private Limited in the month of December 2023

HYDERABAD
Date: 29.03.2024


 Managing Director




LIMITED REVIEW REPORT

To,
The Board Members of
Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited consolidated financial results of M/s Celestial Biolabs Limited for quarter ended 31 December ,2023", and year to date results for the period from 01 April 2023 to 31 December 2023 ("The statement")

The statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated Financial Results , prepared in accordance with applicable accounting standards specified under section 33 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.



We draw your attention to note 4 to the consolidated financial results, where the management had commented that the previous year comparatives are based on the financial statements approved by the board of directors but not yet adopted by the shareholders in the annual General Meeting (AGM) as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting. Our review is carried on based on these unadopted financial results carried forward to the current period.

We draw attention to Note 5 to the consolidated financial results, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 5 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

For M Surendra & Associates
Chartered Accountants
Firm Reg No. 017280S

P. Shaik Shaivali P

CA Shaik Shaivali P
Partner
M.No. 245517



Place : Hyderabad
Date: 27.03.2024

UDIN: 24245517BKDASL1924

CELESTIAL BIOLABS LIMITED
Plot No.59, Road No.12, TSIC Tech Park, IDA Nacharam, Hyderabad-500 076
CONSOLIDATED STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st Dec, 2023

SL.NO.	PARTICULARS	Rs In lacs					
		Quarter Ended			Nine month period ended		Year Ended
		31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.03.2023 (Audited)
I	a) Revenue from operations	3.68	3.58	3.38	9.52	13.07	16.87
II	b) Other Income	-	-	-	-	-	-
III	Total income (I+II)	3.68	3.58	3.38	9.52	13.07	16.87
IV	Expenditure						
	a) Cost of raw and packing materials consumed	2.36	2.17	2.15	5.86	8.02	10.61
	b) Purchase of Traded Products	-	-	-	-	-	-
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	-	-	-	-	-	-
	d) Employee Benefits Expense	2.67	3.01	5.15	9.78	13.86	20.04
	e) Depreciation and amortization	0.54	0.54	0.70	1.62	2.10	2.83
	f) Finance Cost	0.07	0.04	0.07	0.15	0.22	0.83
	g) Other Expenses	1.84	1.08	10.58	9.18	22.47	40.69
	Total expenses	7.48	6.84	18.65	26.59	46.67	75.00
V	Profit / (Loss) before exceptional items and Tax (III-IV)	(3.80)	(3.26)	(15.27)	(17.07)	(33.60)	(58.13)
VI	Exceptional items	-	-	-	-	-	-
VII	Profit / (Loss) before tax (V-VI)	(3.80)	(3.26)	(15.27)	(17.07)	(33.60)	(58.13)
VIII	Tax expense	-	-	-	-	-	-
IX	Net Profit / (Loss) for the period (VII-VIII)	(3.80)	(3.26)	(15.27)	(17.07)	(33.60)	(58.13)
	- Pertaining to owners of the company	(3.62)	(3.18)	(15.27)	(16.53)	(33.60)	(57.67)
	- Pertaining to non controlling interest	(0.18)	(0.08)	-	(0.53)	-	(0.46)
X	Other Comprehensive Income,	-	-	-	-	-	-
	Total Other Comprehensive Income, net of Tax	-	-	-	-	-	-
XI	Total Comprehensive Income for the period	(3.80)	(3.26)	(15.27)	(17.07)	(33.60)	(58.13)
	- Pertaining to owners of the company	(3.62)	(3.18)	(15.27)	(16.53)	(33.60)	(57.67)
	- Pertaining to non controlling interest	(0.18)	(0.08)	-	(0.53)	-	(0.46)
XII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63
XIII	Earning Per Share for the Period						
	Basic	(0.02)	(0.01)	(0.07)	(0.07)	(0.15)	(0.26)
	Diluted	(0.02)	(0.01)	(0.07)	(0.07)	(0.15)	(0.26)

Notes:

- The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 29.03.2024
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
- The Financial results and other financial information for the quarter ended 31st December,2023 has been compiled by the management as per Ind AS, after exercising necessary due diligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only subject to review of statutory auditors. Results are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com
- The previous year comparatives are based on the audited financial statements which are approved by the board of directors but yet to be adopted by the shareholders in the upcoming Annual general meeting as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting
- During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs. Consequently, the Networth which was at 10,227.30 at the beginning of the financial year 2019-20 came down to Rs. 277.86 lakhs for year ended 31.3.2023. Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation
- The company acquired 51.01% shares in X Ploro Chemistry capability centre Private Limited in the month of December 2022

HYDERABAD
Date: 29.03.2024





LIMITED REVIEW REPORT

To,
The Board Members of
Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited standalone financial results of M/s Celestial Biolabs Limited for quarter ended 30 September, 2023", and year to date results for the period from 01 April 2023 to 30 September 2023 ("The statement")

The statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone Financial Results, prepared in accordance with applicable accounting standards specified under section 33 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.



We draw your attention to note 4 to the standalone financial results, where the management had commented that the previous year comparatives are based on the financial statements approved by the board of directors but not yet adopted by the shareholders in the annual General Meeting (AGM) as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting. Our review is carried on based on these unadopted financial results carried forward to the current period.

We draw attention to Note 5 to the standalone financial results, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 5 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

Our conclusion is not modified in respect of this matter

Place : Hyderabad
Date: 29.03.2024

For M Surendra & Associates
Chartered Accountants
Firm Reg No. 017280S

P. Shaik Shavali P

CA Shaik Shavali P
Partner
M.No. 245517



UDIN: 24245517BKDASG3888

STANDALONE BALANCE SHEET		
Particulars	September 30, 2023	March 31, 2023
ASSETS		
Non- current assets		
(a) Property, Plant & Equipment	6.90	7.98
(b) Capital work - in - progress	1,281.58	1,281.58
(c) Financial Assets		
(i) Investments in subsidiary company	0.29	0.29
	1,288.77	1,289.85
Current Assets		
(a) Inventories	2.55	3.38
(b) Financial Assets		
(i) Trade receivables	366.87	370.75
(ii) Cash and cash equivalents	2.15	1.71
(iii) Other financial asset		
(c) Current Tax Assets (Net)		
(d) Other Current Assets	37.74	37.74
	409.31	413.58
TOTAL	1,698.08	1,703.43
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity share capital	2,258.63	2,258.63
(b) Other Equity	-1,993.91	-1,980.78
Total equity	264.72	277.85
LIABILITIES		
Non- current liabilities		
(a) Financial Liabilities		
(i). Borrowings	886.98	885.81
(ii). Trade Payables		
(b) Deferred tax liabilities (Net)		
	886.98	885.81
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	305.33	305.33
(ii) Trade payables		
(a) Dues of micro enterprise and small enterprises		
(b) Dues of creditors other than, micro enterprises and small enterprises	33.26	26.73
(iii) Other financial liabilities	25.00	25.00
b) Other current liabilities	182.78	182.71
c) Provisins		
Income Tax liabilities(net)		
	546.37	539.77
TOTAL	1,698.08	1,703.43
	0.00	-

HYDERABAD
Date: 29.03.2024


Managing Director

CELESTIAL BIOLABS LIMITED
 Plot No.59, Road No.12, TSIC Tech Park, IDA Nacharam, Hyderabad-500 076
STANDALONE STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th Sep, 2023

SL.NO.	PARTICULARS	Rs In lacs					
		Quarter Ended			Six month period ended		Year Ended
		30.09.2023 (Unaudited)	30.06.2023 (Unaudited)	30.09.2022 (Unaudited)	30.09.2023 (Unaudited)	30.09.2022 (Unaudited)	31.03.2023 (Audited)
I	a) Revenue from operations	3.58	2.26	4.18	5.84	9.69	16.87
II	b) Other Income	-	-	-	-	-	-
III	Total income (I+II)	3.58	2.26	4.18	5.84	9.69	16.87
IV	Expenditure						
	a) Cost of raw and packing materials consumed	2.17	1.33	2.51	3.50	5.87	10.61
	b) Purchase of Traded Products	-	-	-	-	-	-
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	-	-	-	-	-	-
	d) Employee Benefits Expense	3.01	4.10	4.53	7.11	8.70	20.04
	e) Depreciation and amortization	0.54	0.54	0.70	1.08	1.41	2.83
	f) Finance Cost	0.04	0.04	0.07	0.08	0.16	0.83
	g) Other Expenses	1.08	6.12	4.56	7.20	11.89	40.69
	Total expenses	6.84	12.13	12.38	18.97	28.03	75.00
V	Profit / (Loss) before exceptional items and Tax (III-IV)	(3.26)	(9.87)	(8.20)	(13.13)	(18.35)	(58.13)
VI	Exceptional items	-	-	-	-	-	-
VII	Profit / (Loss) before tax (V-VI)	(3.26)	(9.87)	(8.20)	(13.13)	(18.35)	(58.13)
VIII	Tax expense	-	-	-	-	-	-
IX	Net Profit / (Loss) for the period (VII-VIII)	(3.26)	(9.87)	(8.20)	(13.13)	(18.35)	(58.13)
X	Other Comprehensive Income,	-	-	-	-	-	-
	Total Other Comprehensive Income, net of Tax	-	-	-	-	-	-
XI	Total Comprehensive Income for the period	(3.26)	(9.87)	(8.20)	(13.13)	(18.35)	(58.13)
XII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63
XIII	Earning Per Share for the Period						
	Basic	(0.01)	(0.04)	(0.04)	(0.06)	(0.08)	(0.26)
	Diluted	(0.01)	(0.04)	(0.04)	(0.06)	(0.08)	(0.26)

Notes

- The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 29.03.2024
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
- The Financial results and other financial information for the quarter ended 30th September, 2023 has been compiled by the management as per Ind AS, after exercising necessary due diligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only subject to review of statutory auditors. Results are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com
- The previous year comparatives are based on the audited financial statements which are approved by the board of directors but yet to be adopted by the shareholders in the upcoming Annual general meeting as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting
- During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs. Consequently, the Networth which was at 10,227.30 lakhs at the beginning of the financial year 2019-20 came down to Rs. 277.86 lakhs for year ended 31.3.2023. Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation
- The company acquired 51.01% shares in X Ploro Chemistry capability centre Private Limited in the month of December 2022

HYDERABAD
Date: 29.03.2024


Managing Director

CELESTIAL
BIOLABS LIMITED

Standalone Cash Flow Statement For the Quarter ended 30th September, 2023

Particulars	Six months ended Sep 30, 2023	Six months ended Sep 30, 2022	year ended ended 31.03.2023
A. Cash Flow From Operating Activities			
Net Profit before Tax & Appropriations	(13.13)	(18.35)	(57.19)
Depreciation & Amortisation of Intangible assets	1.08	1.41	2.83
Operating Profit Before Working Capital Charges	(12.05)	(16.94)	(54.36)
Adjustments for:			
(Increase)/Decrease in Inventory	0.83	0.81	1.50
(Increase)/Decrease in Trade Receivables	3.87	8.49	12.52
(Increase)/Decrease in Other Current Assets	-	(5.06)	-
(Increase)/Decrease in Trade Payable	6.54	(2.24)	0.71
(Increase)/Decrease in Other financial liabilities	-	-	-
(Increase)/Decrease in Other Current Liabilities	0.07	4.49	5.07
(Increase)/Decrease in Provisions	-	-	-
Cash Generated from Operations	(0.73)	(10.44)	(34.56)
Net Cash generated from Operating Activities (A)	(0.73)	(10.44)	(34.56)
B. Cash Flow from Investing Activities:			
Purchases of fixed assets	-	-	(0.64)
Sale of Land and Building	-	(0.64)	-
Investments in subsidiaries	-	-	(0.29)
Net Cash generated from/(Used) Investing Activities (B)	-	(0.64)	(0.93)
C. Cash Flow from Financial Activities			
Net Cash generated from/(used) Financial Activities (c)			
Increase/(Decrease) in Borrowings	1.17	12.23	37.07
Interest and Financial Charges Paid	-	-	-
	1.17	12.23	37.07
Net Increase/(Decrease) in Cash and Cash Equalants (A+B+C)	0.44	1.16	1.58
Cash and Cash equalants at the beginning of the year	1.71	0.13	0.13
Cash and Cash equalants (Closing Balance)	2.15	1.29	1.71

HYDERABAD
Date: 29.03.2024


Managing Director



LIMITED REVIEW REPORT


To,
The Board Members of
Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited consolidated financial results of M/s Celestial Biolabs Limited for quarter ended 30 September ,2023", and year to date results for the period from 01 April 2023 to 30 September 2023 ("The statement")

The statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated Financial Results , prepared in accordance with applicable accounting standards specified under section 33 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.



We draw your attention to note 4 to the consolidated financial results, where the management had commented that the previous year comparatives are based on the financial statements approved by the board of directors but not yet adopted by the shareholders in the annual General Meeting (AGM) as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting. Our review is carried on based on these unadopted financial results carried forward to the current period.

We draw attention to Note 5 to the consolidated financial results, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 5 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

For **M Surendra & Associates**
Chartered Accountants
Firm Reg No. 017280S

P. Shaik Shavali P



CA Shaik Shavali P
Partner
M.No. 245517

Place : Hyderabad
Date: 29.03.2024

UDIN: 24245517BKDASK7091

CONSOLIDATED BALANCE SHEET		
Particulars	September 30, 2023	March 31, 2023
ASSETS		
Non- current assets		
(a) Property, Plant & Equipment	6.90	7.98
(b) Capital work - in - progress	1,281.58	1,281.58
(c) Goodwill	0.10	0.10
(c) Financial Assets	-	-
(i) Investments in subsidiary company	-	-
	1,288.58	1,289.66
Current Assets		
(a) Inventories	2.55	3.38
(b) Financial Assets	-	-
(i) Trade receivables	366.87	370.76
(ii) Cash and cash equivalents	2.61	2.33
(iii) Other financial asset	-	-
(c) Current Tax Assets (Net)	-	-
(d) Other Current Assets	57.56	57.53
	429.59	434.01
TOTAL		
	1,718.17	1,723.67
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity share capital	2,258.63	2,258.63
(b) Other Equity	-1,994.48	-1,981.26
(c) Non controlling interest	-0.37	-0.29
Total equity	263.78	277.08
LIABILITIES		
Non- current liabilities		
(a) Financial Liabilities	-	-
(i). Borrowings	898.91	897.74
(ii). Trade Payables	-	-
(b) Deferred tax liabilities (Net)	-	-
	898.91	897.74
Current liabilities		
(a) Financial Liabilities	-	-
(i) Borrowings	305.33	305.33
(ii) Trade payables	-	-
(a) Dues of micro enterprise and small enterprises	-	-
(b) Dues of creditors other than, micro enterprises and small enterprises	41.95	35.39
(iii) Other financial liabilities	25.00	25.00
b) Other current liabilities	183.21	183.12
c) Provisins	-	-
Income Tax liabilities(net)	-	-
	555.49	548.85
TOTAL		
	1,718.17	1,723.67

HYDERABAD
Date: 29.03.2024


 Managing Director
 

CELESTIAL BIOLABS LIMITED
Plot No.59, Road No.12, TSIIC Tech Park, IDA Nacharam, Hyderabad-500 076
CONSOLIDATED STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th Sep, 2023

SL.NO.	PARTICULARS	Rs In lacs					
		Quarter Ended			Six month period ended		Year Ended
		30.09.2023 (Unaudited)	30.06.2023 (Unaudited)	30.09.2022 (Unaudited)	30.09.2023 (Unaudited)	30.09.2022 (Unaudited)	31.03.2023 (Audited)
I	a) Revenue from operations :						
II	b) Other Income	3.58	2.26	4.18	5.84	9.69	16.87
III	Total income (I+II)	3.58	2.26	4.18	5.84	9.69	16.87
IV	Expenditure						
	a) Cost of raw and packing materials consumed						
	b) Purchase of Traded Products	2.17	1.33	2.51	3.50	5.87	10.61
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	-	-	-	-	-	-
	d) Employee Benefits Expense	3.01	4.10	4.53	7.11	8.70	20.04
	e) Depreciation and amortization	0.54	0.54	0.70	1.08	1.41	2.83
	f) Finance Cost	0.04	0.05	0.07	0.09	0.16	0.83
	g) Other Expenses	1.24	6.12	4.56	7.53	11.89	40.69
	Total expenses	7.00	12.14	12.38	19.31	28.03	75.01
V	Profit / (Loss) before exceptional items and Tax (III-IV)	(3.42)	(9.88)	(8.20)	(13.47)	(18.35)	(58.14)
VI	Exceptional items	-	-	-	-	-	-
VII	Profit / (Loss) before tax (V-VI)	(3.42)	(9.88)	(8.20)	(13.47)	(18.35)	(58.14)
VIII	Tax expense	-	-	-	-	-	-
IX	Net Profit / (Loss) for the period (VII-VIII)	(3.42)	(9.88)	(8.20)	(13.47)	(18.35)	(58.14)
	- Pertaining to owners of the company	(3.26)	(9.88)	(8.20)	(13.38)	(18.35)	(57.67)
	- Pertaining to non controlling interest	(0.16)	(0.00)	-	(0.08)	-	(0.46)
X	Other Comprehensive Income,	-	-	-	-	-	-
	Total Other Comprehensive Income, net of Tax	-	-	-	-	-	-
XI	Total Comprehensive Income for the period	(3.42)	(9.88)	(8.20)	(13.47)	(18.35)	(58.14)
	- Pertaining to owners of the company	(3.26)	(9.88)	(8.20)	(13.38)	(18.35)	(57.67)
	- Pertaining to non controlling interest	(0.16)	(0.00)	-	(0.08)	-	(0.46)
XII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63
XIII	Earning Per Share for the Period						
	Basic	(0.01)	(0.04)	(0.04)	(0.06)	(0.08)	(0.26)
	Diluted	(0.01)	(0.04)	(0.04)	(0.06)	(0.08)	(0.26)

Notes

- The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 29.03.2024
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
- The Financial results and other financial information for the quarter ended 30th September,2023 has been compiled by the management as per Ind AS, after exercising necessary due diligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only subject to review of statutory auditors. Results are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com
- The previous year comparatives are based on the audited financial statements which are approved by the board of directors but yet to be adopted by the shareholders in the upcoming Annual general meeting as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting
- During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs Consequently, the Networth which was at 10,227.30 lakhs at the beginning of the financial year 2019-20 came down to Rs. 277.86 lakhs for year ended 31.3.2023 Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under-going concern basis of preparation
- The company acquired 31.01% shares in X Ploro Chemistry capability centre Private Limited in the month of December 2022.

HYDERABAD
Date: 29.03.2024


Managing Director



**CELESTIAL
BIOLABS LIMITED**

Consolidated Cash Flow Statement For the Quarter ended 30th September, 2023

Particulars	Six months ended Sep 30, 2023	Six months ended Sep 30, 2022	year ended ended 31.03. 2023
A. Cash Flow From Operating Activities			
Net Profit before Tax & Appropriations	(13.47)	(18.35)	(58.14)
Depreciation & Amortisation of Intangible assets	1.08	1.41	2.83
Operating Profit Before Working Capital Charges	(12.39)	(16.94)	(55.31)
Adjustments for:			
(Increase)/Decrease in Inventory	0.83	0.81	1.50
(Increase)/Decrease in Trade Receivables	4.04	8.49	12.52
(Increase)/Decrease in Other Current Assets	(0.03)	(5.06)	(2.17)
(Increase)/Decrease in Trade Payable	6.56	(2.24)	2.43
(Increase)/Decrease in Other financial liabilities			-
(Increase)/Decrease in Other Current Liabilities	0.08	4.49	5.49
(Increase)/Decrease in Provisions			-
Cash Generated from Operations	(0.90)	(10.44)	(35.56)
Net Cash generated from Operating Activities (A)	(0.90)	(10.44)	(35.56)
B. Cash Flow from Investing Activities:			
Purchases of fixed assets	0.00		(0.64)
Sale of Land and Building		(0.64)	-
Capital work in progress			-
Other intangible assets			-
Intangible assets under development			-
Impact of subsidiary acquired in the business combination			(0.29)
Net Cash generated from/(Used) Investing Activities (B)	0.00	(0.64)	(0.93)
C. Cash Flow from Financial Activities			
Increase/(Decrease) in Borrowings	1.17	12.23	37.61
Interest and Financial Charges Paid			-
Net Cash generated from/(used) Financial Activities (c)	1.17	12.23	37.61
Net Increase/(Decrease) in Cash and Cash Equalants (A+B+C)	0.28	1.16	1.12
Cash and Cash equalants at the beginning of the year	2.33	0.13	0.13
Cash and Cash equalants Acquired in the business combination			
Cash and Cash equalants (Closing Balance)	2.61	1.29	2.32

HYDERABAD
Date: 29.03.2024


Managing Director





M. SURENDRA & ASSOCIATES
Chartered Accountants

LIMITED REVIEW REPORT

To,
The Board Members of
Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited standalone financial results of M/s Celestial Biolabs Limited for quarter ended 30 June ,2023", ("The statement")

This statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone Financial Results , prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.

We draw your attention to note 4 to the standalone financial results, where the management had commented that the previous year comparatives are based on the financial statements approved by the board of directors but not yet adopted by the shareholders in the annual General Meeting (AGM) as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting. Our review is carried on based on these unadopted financial results carried forward to the current period.



We draw attention to Note 5 to the standalone financial results, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 5 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

Our conclusion is not modified in respect of this matter.

For M Surendra & Associates

Chartered Accountants

Firm Reg No. 017280S

P. Shaik 4/15

CA Shaik Shavali P

Partner

M.No. 245517



Place : Hyderabad

Date: 29.03.2024

UDIN: 24245517BKDASF8507



CELESTIAL BIOLABS LIMITED
 Plot No 82, Venkat Reddy Nagar, Narapally, Medchal, Malkajgiri Dist Hyderabad - 500039
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2023

SL.NO.	PARTICULARS	Rs In lacs			
		Quarter Ended		Year Ended	
		30.06.2023 (Unaudited)	31.03.2023 (Audited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)
I	a) Revenue from operations	2.26	3.79	5.51	16.87
II	b) Other Income	-	-	-	-
III	Total income (I+II)	2.26	3.79	5.51	16.87
IV	Expenditure				
	a) Cost of raw and packing materials consumed	1.33	2.59	3.36	10.61
	b) Purchase of Traded Products	-	-	-	-
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	-	-	-	-
	d) Employee Benefits Expense	4.10	6.18	4.18	20.04
	e) Depreciation and amortization	0.54	0.73	0.70	2.83
	f) Finance Cost	0.04	0.01	0.08	0.23
	g) Other Expenses	6.12	17.87	7.33	40.34
	Total expenses	12.13	27.38	15.66	74.05
V	Profit / (Loss) before exceptional items and Tax (III-IV)	(9.87)	(23.59)	(10.15)	(57.18)
VI	Exceptional Items	-	-	-	-
VII	Profit / (Loss) before tax (V-VI)	(9.87)	(23.59)	(10.15)	(57.18)
VIII	Tax expense	-	-	-	-
IX	Net Profit / (Loss) for the period (VII-VIII)	(9.87)	(23.59)	(10.15)	(57.18)
X	Other Comprehensive Income, Total Other Comprehensive Income, net of Tax	-	-	-	-
XI	Total Comprehensive Income for the period	(9.87)	(23.59)	(10.15)	(57.18)
XII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	2,258.63
XIII	Earning Per Share for the Period				
	Basic	(0.04)	(0.10)	(0.04)	(0.25)
	Diluted	(0.04)	(0.10)	(0.04)	(0.25)

Notes

- The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 29.03.2024.
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
- The Financial results and other financial information for the quarter ended 30th June,2023 has been compiled by the management as per Ind AS, after exercising necessary due diligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only sbject to review of statutory auditors. Results are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com
- The previous year comparatives are based on the audited financial statements which are approved by the board of directors but yet to be adopted by the shareholders in the upcoming Anual general meeting as the company has not complied with section 96 of the companies act 2013 regarding conduction of Anual general meeting
- During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs. Consequently, the Networth which was at 10,227.30 lakhs at the beginning of the financial year 2019-20 came down to Rs. 277.66 lakhs for year ended 31.3.2023. Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation
- The company acquired 51.01% shares in X Ploro Chemistry capability centre Private Limited in the month of December 2023.

HYDERABAD
 Date: 29.03.2024


 Managing Director




M. SURENDRA & ASSOCIATES
Chartered Accountants

LIMITED REVIEW REPORT

To,
The Board Members of
Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited consolidated financial results of M/s Celestial Biolabs Limited for quarter ended 30 June ,2023", ("The statement")

This statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated Financial Results , prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.

We draw your attention to note 4 to the consolidated financial results, where the management had commented that the previous year comparatives are based on the financial statements approved by the board of directors but not yet adopted by the shareholders in the annual General Meeting (AGM) as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting. Our review is carried on based on these unadopted financial results carried forward to the current period.



We draw attention to Note 5 to consolidated financial results, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 5 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

For M Surendra & Associates

Chartered Accountants

Firm Reg No. 017280S

P. Shaik Shaivali P



CA Shaik Shavali P

Partner

M.No. 245517

Place : Hyderabad

Date: 29.03.2024

UDIN: 24245517BKDASI4253

CELESTIAL BIOLABS LIMITED
 Plot No 82, Venkat Reddy Nagar, Narapally, Medchal, Malkajgiri Dist Hyderabad - 500039
CONSOLIDATION STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2023

SL.NO.	PARTICULARS	Rs In lacs			
		Quarter Ended		Year Ended	
		30.06.2023 (Unaudited)	31.03.2023 (Audited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)
I	a) Revenue from operations				
II	b) Other Income	2.26	3.79	5.51	16.87
III	Total income (I+II)				
IV	Expenditure	2.26	3.79	5.51	16.87
	a) Cost of raw and packing materials consumed				
	b) Purchase of Traded Products	1.33	2.59	3.36	10.61
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	-	-	-	-
	d) Employee Benefits Expense				
	e) Depreciation and amortization	4.10	6.18	4.18	20.04
	f) Finance Cost	0.54	0.73	0.70	2.83
	g) Other Expenses	0.05	0.61	0.08	0.83
	Total expenses	6.12	18.22	7.33	40.69
V	Profit / (Loss) before exceptional items and Tax (III-IV)	12.14	28.33	15.66	75.00
VI	Exceptional items	(9.88)	(24.54)	(10.15)	(58.13)
VII	Profit / (Loss) before tax (V-VI)	-	-	-	-
VIII	Tax expense	(9.88)	(24.54)	(10.15)	(58.13)
IX	Net Profit / (Loss) for the period (VII-VIII)	-	-	-	-
	- Pertaining to owners of the company	(9.88)	(24.54)	(10.15)	(58.13)
	- Pertaining to non controlling interest	(9.88)	(24.08)	(10.15)	(57.67)
X	Other Comprehensive Income	(0.00)	(0.46)	-	(0.46)
	Total Other Comprehensive Income, net of Tax	-	-	-	-
XI	Total Comprehensive Income for the period	-	-	-	-
	- Pertaining to owners of the company	(9.88)	(24.54)	(10.15)	(58.13)
	- Pertaining to non controlling interest	(9.88)	(24.08)	(10.15)	(57.67)
XII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	2,258.63
XIII	Earning Per Share for the Period				
	Basic	(0.04)	(0.11)	(0.04)	(0.26)
	Diluted	(0.04)	(0.11)	(0.04)	(0.26)

Notes

- The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 29.03.2024
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
- The Financial results and other financial information for the quarter ended 30th June, 2023 has been compiled by the management as per Ind AS, after exercising necessary due diligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only subject to review of statutory auditors. Results are available on the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com
- The previous year comparatives are based on the audited financial statements which are approved by the board of directors but yet to be adopted by the shareholders in the upcoming Annual general meeting as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting
- During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs. Consequently, the Networth which was at 10,227.30 lakhs at the beginning of the financial year 2019-20 came down to Rs. 277.86 lakhs for year ended 31.3.2023. Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions: mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation.
- The company acquired 51.01% shares in X Piro Chemistry capability centre Private Limited in the month of December 2022.

HYDERABAD
Date: 29.03.2024


 Managing Director



STANDALONE BALANCE SHEET		(Amounts in Rs. Lakhs)	
Particulars	March 31, 2023	March 31, 2022	
ASSETS			
Non- current assets			
(a) Property, Plant & Equipment	7.98	10.16	
(b) Capital work - in - progress	1,281.58	1,281.58	
(c) Financial Assets			
(i) Investments in subsidiaries	0.29	-	
	1,289.84	1,291.74	
Current Assets			
(a) Inventories			
(b) Financial Assets	3.38	4.88	
(i) Trade receivables			
(ii) Cash and cash equivalents	370.76	383.28	
(iii) Other financial asset	1.71	0.13	
(c) Current Tax Assets (Net)	-	-	
(d) Other Current Assets	37.74	37.74	
	413.60	426.03	
TOTAL			
	1,703.44	1,717.77	
EQUITY AND LIABILITIES			
EQUITY			
(a) Equity share capital	2,258.63	2,258.63	
(b) Other Equity	(1,980.77)	(1,923.59)	
Total equity	277.86	335.04	
LIABILITIES			
Non- current liabilities			
(a) Financial Liabilities			
(i). Borrowings			
(ii). Trade Payables	885.81	848.74	
(b) Deferred tax liabilities (Net)	-	-	
	885.81	848.74	
Current liabilities			
(a) Financial Liabilities			
(i) Borrowings			
(ii) Trade payables	305.33	305.33	
(a) Dues of micro enterprise and small enterprises	-	-	
(b) Dues of creditors other than, micro enterprises and small enterprises	26.73	26.01	
(iii) Other financial liabilities	25.00	25.00	
b) Other current liabilities	182.71	177.63	
c) Provisions	-	-	
Income Tax liabilities(net)	-	-	
	539.77	533.98	
TOTAL			
	1,703.44	1,717.76	

As per our report of even date

For M Surendra & Associates
Chartered Accountants
Firm Reg 017280S
P. Shaik
CA Shaik Shavali P
Partner
MRN: 245517



For and on Behalf of the Board
Celestial Biolabs Limited
CIN: L72200TG190724003274
Amrit Kumar Singh
Managing Director
DIN: 01824426
Padma Singh
Director
DIN: 01448915



Place: Hyderabad
Date: 29.03.2024

**CELESTIAL
BIOLABS LIMITED**

Standalone Cash Flow Statement For the year ended 31st March, 2023

Particulars	(Amounts in Rs. Lakhs)	
	2022-23	2021-22
A. Cash Flow From Operating Activities		
Net Profit before Tax & Appropriations		
Depreciation	(57.19)	(40.95)
Provison for tax	2.83	3.02
Operating Profit Before Working Capital Charges		-
Adjustments for:	(54.36)	(37.93)
(Increase)/Decrease in Inventory	1.50	0.33
(Increase)/Decrease in Trade Receivables	12.52	(5.26)
(Increase)/Decrease in Other Curent Assets		
(Increase)/Decrease in Trade Payable	0.71	(11.89)
(Increase)/Decrease in Other financial liabilities	-	25.00
(Increase)/Decrease in Other Current Liabilities	5.08	2.23
(Increase)/Decrease in Provisions	-	-
Cash Generated from Operations	(34.56)	(27.52)
Net Cash generated from Operating Activities (A)	(34.56)	(27.52)
B. Cash Flow from Investing Activities:		
Purchase of fixed assets		
Investments In subsidiaries	(0.65)	(0.38)
Product development expenses	(0.29)	-
Net Cash generated from/(Used) Investing Activities (B)	(0.93)	(0.38)
C. Cash Flow from Financial Activities		
Increase/(Decrease) in Borrowings		
Net Cash generated from/(used) Financial Activities (c)	37.07	25.89
Net Increase/(Decrease) in Cash and Cash Equalants (A+B+C)	37.07	25.89
Cash and Cash Equivalent at the beginning of the year	1.58	(2.01)
Cash and Cash Equivalent (Closing Balance)	0.13	2.13
	1.71	0.13

As per our report of even date

For M Surendra & Associates
Chartered Accountants
Firm Reg 017280S

CA Shaik Shavali P
Partner
MRN: 245517



For and on Behalf of the Board
Celestial Biolabs Limited

CIN: L72200TG1997PLC028374

Amit Kumar Singh
Managing Director
DIN: 01824426

Padma Singh
Director
DIN: 01448915

Place: Hyderabad
Date: 29.03.2024

CELESTIAL BIOLABS LIMITED
 Plot No.59, Road No.12, TSIC Tech Park, IDA Nacharam, Hyderabad-500 076
STANDALONE STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st March, 2023

SL.NO.	PARTICULARS	Rs In lacs				
		Quarter Ended			Year to Date	
		31.03.2023 (audited)	31.12.2022 (Unaudited)	31.03.2022 (audited)	31.03.2023 (audited)	31.03.2022 (Audited)
I	a) Revenue from operations					
II	b) Other Income	3.79	3.38	6.31	16.87	14.75
III	Total income (I+II)					
IV	Expenditure	3.79	3.38	6.31	16.87	14.75
	a) Cost of raw and packing materials consumed					
	b) Purchase of Traded Products	2.59	2.15	3.90	10.61	8.92
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	-	-	-	-	-
	d) Employee Benefits Expense	-	-	-	-	-
	e) Depreciation and amortization	6.18	5.15	4.24	20.04	12.33
	f) Finance Cost	0.73	0.70	0.70	2.83	3.02
	g) Other Expenses	0.01	0.07	-	0.23	0.07
	Total expenses	17.87	10.58	24.99	40.35	31.38
V	Profit / (Loss) before exceptional items and Tax (III-IV)	27.39	18.64	33.82	74.06	55.70
VI	Exceptional items	(23.60)	(15.26)	(27.51)	(57.19)	(40.95)
VII	Profit / (Loss) before tax (V-VI)	-	-	-	-	-
VIII	Tax expense	(23.60)	(15.26)	(27.51)	(57.19)	(40.95)
IX	Net Profit / (Loss) for the period (VII-VIII)	-	-	-	-	-
X	Other Comprehensive Income,	(23.60)	(15.26)	(27.51)	(57.19)	(40.95)
	Total Other Comprehensive Income, net of Tax	-	-	-	-	-
XI	Total Comprehensive Income for the period	(23.60)	(15.26)	(27.51)	(57.19)	(40.95)
XII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)					
XIII	Earning Per Share for the Period	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63
	Basic:	(0.10)	(0.07)	(0.12)	(0.25)	(0.18)
	Diluted	(0.10)	(0.07)	(0.12)	(0.25)	(0.18)

Notes

- The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 29.03.2024
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
- The Financial results and other financial information for the quarter ended 31st March, 2023 has been compiled by the management as per Ind AS, after exercising necessary due diligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only subject to review of statutory auditors. Results are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com
- During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs. Consequently, the Networth which was at 10,227.30 at the beginning of the financial year 2019-20 came down to Rs. 277.86 lakhs for year ended 31.3.2023. Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation
- The company acquired 51.01% shares in X Ploro Chemistry capability centre Private Limited in the month of December 2022

For M Surendra & Associates
 Chartered Accountants
 Firm Reg 017280S

CA Shaik Shavali P
 Partner
 MRN: 245517



For and on Behalf of the Board
 Celestial Biolabs Limited
 CIN: L72200TG1997PLC028374

Amit Kumar Singh
 Managing Director
 DIN: 01824426



Padma Singh
 Director
 DIN: 01448915



Place: Hyderabad
 Date: 29.03.2024



INDEPENDENT AUDITOR'S REPORT

To,
The Board Members of
Celestial Biolabs Limited

Opinion

We have audited the accompanying Statement of standalone Financial Results of Celestial Biolabs Limited (the "Company"), for the three months and year ended March 31, 2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- a. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
- b. gives a true and fair view in conformity with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the three months and year ended March 31, 2023.

Basis for Opinion

We conducted our audit of the Statement in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the standalone Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion



Material Uncertainty on Going Concern

We draw attention to note 4 of the Statement, which indicates that the Company has significant losses and its net worth has been significantly eroded, the Company has a net loss during the current year. These conditions, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. However, based upon the measures as set forth in the note 4, including necessary financial support from a significant promoter shareholder, the management and the Board of Directors of the Company have a reasonable expectation that the Company will be able to realise its assets and discharge all its contractual obligations and liabilities as they fall due in near future in the normal course of the business. Accordingly, management has prepared the financial statements on a going concern basis.

Our Opinion is not modified in respect of this matter.

Management's Responsibilities for the Financial Results

These annual financial results have been prepared on the basis of the annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these annual financial results that give a true and fair view of the net profit and other comprehensive loss and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual standalone financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process



Auditor's Responsibilities for the Audit of the Annual standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the annual standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also

- Identify and assess the risks of material misstatement of the annual standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of standalone financial statements on whether the company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual standalone financial results, including the disclosures, and whether the annual standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation
- Obtain sufficient appropriate audit evidence regarding the standalone Financial Results of the Company to express an opinion on the standalone Financial Results.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Emphasis of Matter

The Company has long-term borrowings with State bank of India and the bank sanctioned the One Time Settlement (which has expired on date) for Rs 305.22 lakhs. The Company is carrying the One Time Settlement amount as the closing balance and has not recognized interest expense.

For M Surendra & Associates

Chartered Accountants

Firm Reg No. 017280S

P. Shaik Shaivali P

CA Shaik Shaivali P

Partner

M.No. 245517

UDIN: 24245517 BKDASC 6876



Place : Hyderabad

Date: 29.03.2024

CONSOLIDATED BALANCE SHEET		Amount in Lacs	
Particulars	March 31, 2023	March 31, 2022	
ASSETS			
Non- current assets			
(a) Property, Plant & Equipment	7.98	10.16	
(b) Capital work - in - progress	1,281.58	1,281.58	
(c) Goodwill	0.10	-	
	1,289.66	1,291.74	
Current Assets			
(a) Inventories	3.38	4.88	
(b) Financial Assets	-	-	
(i) Trade receivables	370.76	383.28	
(ii) Cash and cash equivalents	2.33	0.13	
(iii) Other financial asset	-	-	
(c) Current Tax Assets (Net)	-	-	
(d) Other Current Assets	57.53	37.74	
	434.01	426.03	
TOTAL		1,723.67	1,717.77
EQUITY AND LIABILITIES			
EQUITY			
(a) Equity share capital	2,258.63	2,258.63	
(b) Other Equity	(1,981.26)	(1,923.59)	
(c) Non controlling interest	-0.29	-	
Total equity	277.08	335.04	
LIABILITIES			
Non- current liabilities			
(a) Financial Liabilities	-	-	
(i). Borrowings	897.74	848.74	
(ii). Trade Payables	-	-	
(b) Deferred tax liabilities (Net)	-	-	
	897.74	848.74	
Current liabilities			
(a) Financial Liabilities	-	-	
(i) Borrowings	305.33	305.33	
(ii) Trade payables	-	-	
(a) Dues of micro enterprise and small enterprises	-	-	
(b) Dues of creditors other than, micro enterprises and small enterprises	35.39	26.01	
(iii) Other financial liabilities	25.00	25.00	
b) Other current liabilities	183.12	177.64	
c) Provisins	-	-	
Income Tax liabilities(net)	-	-	
	548.84	533.98	
TOTAL		1,723.67	1,717.77
	-0.00	-	

As per our report of even date

For M Surendra & Associates
Chartered Accountants
Firm Reg No 017280S

CA Shaik Shavali P
Partner
MRN: 245517



For and on Behalf of the Board
Celestial Biolabs Limited
CIN: L72200TG1997PLC028504

Anil Kumar Singh
Managing Director
DIN: 01824426



Pradna Singh
Director
DIN: 01448915

Place: Hyderabad
Date: 29.03.2024

CELESTIAL BIOLABS LIMITED
Plot No.59, Road No.12, TSIC Tech Park, IDA Nacharam, Hyderabad-500 076
CONSOLIDATION STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st March, 2023

SL.NO.	PARTICULARS	Rs In lacs				
		Quarter Ended			Year to Date	
		31.03.2023 (Audited)	31.12.2022 (Unaudited)	31.03.2022 (Unaudited)	31.03.2023 (Audited)	31.03.2022 (Audited)
I	a) Revenue from operations	3.79	3.38	6.31	16.87	14.75
II	b) Other Income	-	-	-	-	-
III	Total Income (I+II)	3.79	3.38	6.31	16.87	14.75
IV	Expenditure					
	a) Cost of raw and packing materials consumed	2.59	2.15	3.90	10.61	8.92
	b) Purchase of Traded Products	-	-	-	-	-
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	-	-	-	-	-
	d) Employee Benefits Expense	6.18	5.15	4.24	20.04	12.32
	e) Depreciation and amortization	0.73	0.70	0.70	2.83	3.02
	f) Finance Cost	0.61	0.07	-	0.83	0.07
	g) Other Expenses	18.22	10.58	24.99	40.69	31.36
	Total expenses	28.33	18.64	33.82	75.00	55.69
V	Profit / (Loss) before exceptional items and Tax (III-IV)	(24.54)	(15.26)	(27.51)	(58.13)	(40.94)
VI	Exceptional items	-	-	-	-	-
VII	Profit / (Loss) before tax (V-VI)	(24.54)	(15.26)	(27.51)	(58.13)	(40.94)
VIII	Tax expense	-	-	-	-	-
IX	Net Profit / (Loss) for the period (VII-VIII)	(24.54)	(15.26)	(27.51)	(58.13)	(40.94)
	- Pertaining to owners of the company	(24.08)	-	-	(57.67)	-
	- Pertaining to non controlling interest	(0.46)	-	-	(0.46)	-
X	Other Comprehensive Income,	-	-	-	-	-
	Total Other Comprehensive Income, net of Tax	-	-	-	-	-
XI	Total Comprehensive Income for the period	(24.54)	(15.26)	(27.51)	(58.13)	(40.94)
XII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63
XIII	Earning Per Share for the Period					
	Basic	(0.11)	(0.07)	(0.12)	(0.26)	(0.18)
	Diluted	(0.11)	(0.07)	(0.12)	(0.26)	(0.18)

- Notes
- The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 29.03.2024
 - Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
 - The Financial results and other financial information for the quarter ended 31st March, 2023 has been compiled by the management as per Ind AS, after exercising necessary due diligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only subject to review of statutory auditors. Results are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com
 - During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs. Consequently, the Networth which was at 10,227.30 at the beginning of the financial year 2019-20 came down to Rs. 277.08 lakhs for year ended 31.3.2023. Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation.
 - The company acquired 51.01% shares in X Puro Chemistry capability centre Private Limited in the month of December 2022

For M Surendra & Associates
Chartered Accountants
Firm Reg No 017280S

CA Shaik Shavali P
Partner
MRN: 245517



For and on Behalf of the Board
Celestial Biolabs Limited
CIN: L72200TG1997PLC028374

Amit Kumar Singh
Managing Director
DIN: 01824426



Place: Hyderabad
Date: 29.03.2024

**CELESTIAL
BIOLABS LIMITED**

Consolidated Cash Flow Statement For the year ended 31st March, 2023

Amount In Lacs

Particulars	2022-23	2021-22
A.Cash Flow From Operating Activities		
Net Profit before Tax & Appropriations	(58.14)	(40.95)
Depreciation	2.83	3.02
Provision for tax	-	-
Operating Profit Before Working Capital Charges	(55.31)	(37.93)
Adjustments for:		
(Increase)/Decrease in Inventory	1.50	0.33
(Increase)/Decrease in Trade Receivables	12.52	(5.26)
(Increase)/Decrease in Other Current Assets	(2.17)	-
(Increase)/Decrease in Trade Payable	2.43	(11.89)
(Increase)/Decrease in Other financial liabilities	-	25.00
(Increase)/Decrease in Other Current Liabilities	5.49	2.23
(Increase)/Decrease in Provisions	-	-
Cash Generated from Operations	(35.56)	(27.52)
Net Cash generated from Operating Activities (A)	(35.56)	(27.52)
B.Cash Flow from Investing Activities:		
Purchase of fixed assets	(0.64)	(0.38)
Capital work in progress	-	-
Other intangible assets	-	-
Intangible assets under development	-	-
Impact of subsidiary acquired in the business combination	(0.29)	-
Interest earned	-	-
Product development expenses	-	-
Net Cash generated from/(Used) Investing Activities (B)	(0.92)	(0.38)
C.Cash Flow from Financial Activities		
Net Cash generated from/(used) Financial Activities (c)	-	-
Increase/(Decrease) in Borrowings	37.61	25.89
	37.61	25.89
Net Increase/(Decrease) in Cash and Cash Equalants (A+B+C)	1.13	(2.01)
Cash and Cash equalants at the beginning of the year	0.13	2.13
Cash and cash equivalents acquired in the business combination	1.07	-
Cash and Cash equalants (Closing Balance)	2.32	0.13

As per our report of even date

For M Surendra & Associates
Chartered Accountants
Firm Reg No 017280S

CA Shaik Shavali P
Partner
MRN: 245517



For and on Behalf of the Board
Celestial Biolabs Limited
CIN: L72200TG1997PLC028374

Amit Kumar Singh
Managing Director
DIN: 01824426

Padma Singh
Director
DIN: 01448915



Place: Hyderabad
Date: 29.03.2024



INDEPENDENT AUDITOR'S REPORT

To,
The Board Members of
Celestial Biolabs Limited

Opinion

We have audited the accompanying Statement of consolidated Financial Results of Celestial Biolabs Limited (the "Company"), for the three months and year ended March 31, 2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- a. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
- b. gives a true and fair view in conformity with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Group for the three months and year ended March 31, 2023.

Basis for Opinion

We conducted our audit of the Statement in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the consolidated Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion

Material Uncertainty on Going Concern

We draw attention to note 4 of the Statement, which indicates that the Group has significant losses and its net worth has been significantly eroded, the Group has a net loss during the current year. These conditions, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. However, based upon the measures as set forth in the note 4, including necessary financial support from a significant promoter shareholder, the management and the Board of Directors of the Company have a reasonable expectation that the Company will be able to realise its assets and discharge all its contractual obligations and liabilities as they fall due in near future in the normal course of the business. Accordingly, management has prepared the consolidated financial statements on a going concern basis.

Our Opinion is not modified in respect of this matter.

Management's Responsibilities for the consolidated Financial Results

These consolidated annual financial results have been prepared on the basis of the annual consolidated financial statements.

The Group's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the net profit and other comprehensive loss and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the annual consolidation financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual consolidation financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of consolidated financial statements on whether the company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation
- Obtain sufficient appropriate audit evidence regarding the consolidated Financial Results of the Company to express an opinion on the consolidated Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Emphasis of Matter

The Company has long-term borrowings with State bank of India and the bank sanctioned the One Time Settlement (which has expired on date) for Rs 305.22 lakhs. The Group is carrying the One Time Settlement amount as the closing balance and has not recognized interest expense.

For **M Surendra & Associates**

Chartered Accountants

Firm Reg No. 017280S

P. Shaik Shavali P

CA Shaik Shavali P

Partner

M.No. 245517



Place : Hyderabad

Date: 29.03.2024

UDIN: 24245517BKDASE1599

Date: 29.03.2024

To,

Department of Corporate Services BSE Limited Floor 25, PJ Towers Dalal Street, Mumbai – 400 001	National Stock Exchange of India Ltd Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai 400 051
---	--

Dear Sir,

Sub: Declaration under Regulation 33(3)(d) of SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015.

We hereby declare under the provisions of SEBI (LODR) Regulations, 2015 that the Auditors of the Company M/s M Surendra and Associates, Chartered Accountants (Firm Regn No. 017280S) have issued Independent Auditor's Report for the financial year 2022-2023 with unmodified opinion on Standalone and Consolidated Financial Statements as prepared under the provisions of Companies Act, 2013.

Kindly acknowledge the receipt of the same.

Thanking you

Yours truly
For Celestial Biolabs Limited

AMIT
KUMAR
SINGH

Digitally signed by
AMIT KUMAR SINGH
Date: 2024.03.29
18:22:20 +05'30'

Amit Kumar Singh
Managing Director
DIN: 01824426